From October 1, 2023 to December 18, 2023, the company has repurchased 73,300 shares, representing 0.62% for CAD 0.62 million. With this, the company has completed the repurchase of 380,000 shares, representing 3.17% for CAD 2.89 million under the buyback announced on December 13, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.51 CAD | -1.62% | -2.07% | -7.70% |
22/04 | BioSyent Inc.(TSXV:RX) dropped from S&P/TSX Venture Composite Index | CI |
01/04 | BioSyent To Present At LD Micro New York Investor Conference | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.70% | 73.28M | |
+32.95% | 700B | |
+26.51% | 569B | |
-4.97% | 358B | |
+18.83% | 330B | |
+3.54% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.70% | 161B |
- Stock Market
- Equities
- RX Stock
- News BioSyent Inc.
- Tranche Update on BioSyent Inc. (TSXV: RX)'s Equity Buyback Plan announced on December 13, 2022.